Department of Health and Human Services, through National Institutes of Health, awarded Syntr Health Technologies, Inc. of Irvine, CA $2,050,527 under the SBIR program (Phase I), with work starting 2025-09-25 and running to 2027-08-31. It is one of 2 SBIR and STTR awards Syntr Health Technologies, Inc. received in the last two years, $2,407,027 in all. Each figure links to the federal record.
The award
| Recipient | Syntr Health Technologies, Inc. (Irvine, CA) |
|---|---|
| Awarding agency | Department of Health and Human Services |
| Awarding office | National Institutes of Health |
| Phase | Phase I |
| Amount obligated | $2,050,527 |
| Period of performance starts | 2025-09-25 |
| Period of performance ends | 2027-08-31 |
| Award number | R44TR004975 (grant, CFDA 93.350) |
| Assistance listing | 93.350, National Center for Advancing Translational Sciences |
| Place of performance | Irvine, Orange County, CA |
| Signed | 2025-09-24 |
| Recipient registry id (UEI) | DTC9T712PUB3 |
Want the whole picture on Syntr Health Technologies, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Syntr Health Technologies, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Syntr Health Technologies, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What it is for
Device automation of an fda-cleared cd-microfluidic platform for rapid tissue microsizing - abstract there is a need in the market for a true platform technology that automates the tissue processing experience. Syntr hea
Funding actions on this award
| Date | Action | Modification | Amount |
|---|---|---|---|
| 2026-08-11 | Continuation | 000 | $1,000,251 |
| 2025-09-24 | Continuation | 000 | $1,050,276 |
Device automation of an fda-cleared cd-microfluidic platform for rapid tissue microsizing - abstract there is a need in the market for a true platform technology that automates the tissue processing experience. Syntr health technologies has dedicated the last nine years to developing the technology that can streamline tissue processing. Our fda-cleared syntrfuge system and SYNTRFPU360, is a platform technology that can process a variety of different tissue types such as cancer tumors of kidney, liver, brain, and breast tissue by dissociating them into single cells to better understand tumor tissue heterogeneity, of which the single cell analysis market is valued at $3.3 billion and expected to grow to $6.3 billion by 2026. Additionally, our platform can be used to microsize autologous adipose tissue to be used for reinjection back into the patient to treat medical conditions of the aging population such as diabetic foot ulcers, knee osteoarthritis, and breast cancer reconstruction surgery. Syntr health successfully completed an SBIR Phase I grant where we utilized microsized adipose tissue to heal diabetic ulcers in an animal model. This study had an important role in developing a treatment modality that translated successfully into humans. Preliminary human clinical data shows significant diabetic foot ulcer wound closure within 28 ± 4 days using autologous adipose tissue proc ...
From the federal award record.
Other SBIR and STTR awards to Syntr Health Technologies, Inc.
| Starts | Agency | Program | Amount | Project |
|---|---|---|---|---|
| 2025-09-02 | Department of Health and Human Services | SBIR Phase I | $356,500 | Accelerating bioengineering approaches for increasing access to new solutions targeting br (record) |
Every other federal award to Syntr Health Technologies, Inc. on record
The federal register lists 4 other awards to the same registry id (UEI DTC9T712PUB3), $1,460,932 in all, from 1 agency.
| Starts | Agency | Amount | Award |
|---|---|---|---|
| 2026-09-22 | National Institutes of Health | $313,372 | Prevention of amputation with rapid healing of diabetic ulcers using autologous microsized fat tissue - projec (R43DK147508) |
| 2025-08-15 | National Institutes of Health | $406,500 | Rapid and automated dissociation of tumor tissue for single cell diagnostics - abstract solid tumors are dive (R43TR005720) |
| 2023-12-15 | National Institutes of Health | $441,060 | Device automation of an fda-cleared cd-microfluidic platform for rapid tissue microsizing - abstract there is (R43TR004975) |
| 2017-09-15 | National Institutes of Health | $300,000 | Mechanical activation of adipose-derived stem cells for the treatment of diabetic foot ulcers using a novel cd (R43DK116389) |
Who runs it, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Syntr Health Technologies, Inc.Look up Syntr Health Technologies, Inc. first. Finding the company and seeing how much is on record uses no credits.
Look up Syntr Health Technologies, Inc.Where this comes from
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs set aside part of federal research budgets for small companies. Agencies award them in phases: Phase I tests whether an idea is feasible, Phase II funds development, and Phase III is follow-on work paid for outside the set-aside. STTR awards also require a research institution as a partner.
Every figure on this page is taken from the award's own federal record, linked beside it, as it stood when the page was built: the recipient, its address, the awarding agency and office, the amount obligated so far, the dates and the description. Phase and program are shown as the award's own description states them. The amount can grow later if the agency adds funding to the same award.